Omr-IgG-am

Omr-IgG-am is an experimental, engineered monoclonal antibody designed for the localized treatment of allergic asthma via inhalation. It is a next-generation 'muco-trapping' variant of omalizumab, an established anti-IgE therapy. Developed by researchers at the University of North Carolina at Chapel Hill and the biotechnology company Mucommune, Omr-IgG-am features a modified Fc region containing 'Ab-mucin' (am) mutations. These mutations, typically involving the introduction of positively charged residues, enhance the antibody's affinity for the negatively charged glycans on mucins (such as MUC5AC and MUC5B) within the airway mucus layer. The mechanism of action involves dual binding: the antibody's Fab domains neutralize free Immunoglobulin E (IgE), while its modified Fc region anchors the antibody-IgE complex to the airway mucus. This 'muco-trapping' effect prevents IgE from diffusing through the mucus to reach and sensitize mast cells and basophils in the underlying respiratory epithelium, thereby inhibiting the allergic inflammatory cascade at its source. This localized approach aims to provide potent protection in the lungs with minimal systemic exposure.

Brand names

Omr-IgG-am

Other names

muco-trapping omalizumabAb-mucin omalizumab